A Single-Center, Randomized, Double-Masked, Placebo and Active Controlled, Dose-Ranging Evaluation of the Duration of Action of Brimonidine Tartrate Ophthalmic Solution in the Control of Ocular Redness Induced by Conjunctival Allergen Challenge (CAC)
| Status: | Archived |
|---|---|
| Conditions: | Allergy, Ocular |
| Therapuetic Areas: | Ophthalmology, Otolaryngology |
| Healthy: | No |
| Age Range: | Any |
| Updated: | 7/1/2011 |
| Start Date: | January 2011 |
| End Date: | May 2011 |
The purpose of this study is to evaluate the safety, efficacy, and dose response of
brimonidine tartrate ophthalmic solution as compared to placebo in the prevention of
allergen-induced conjunctival redness using a conjunctival allergen challenge (CAC) model.
It is hypothesized that low-dose brimonidine tartrate ophthalmic solution will be more
effective than vehicle in the prevention of conjunctival redness induced by conjunctival
allergen challenge when instilled prior to the allergen challenge.
We found this trial at
1
site
Click here to add this to my saved trials
